240 related articles for article (PubMed ID: 26381028)
41. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
42. Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma.
Perret RE; Josselin N; Knol AC; Khammari A; Cassecuel J; Peuvrel L; Dreno B;
Int J Dermatol; 2017 May; 56(5):527-533. PubMed ID: 28188628
[TBL] [Abstract][Full Text] [Related]
43. Nephrotoxicity of the BRAF Inhibitors Vemurafenib and Dabrafenib.
Jhaveri KD; Sakhiya V; Fishbane S
JAMA Oncol; 2015 Nov; 1(8):1133-4. PubMed ID: 26182194
[TBL] [Abstract][Full Text] [Related]
44. Severe erythema exudative multiforme developing from advanced melanoma treated with dabrafenib and trametinib followed by nivolumab.
Fujimura T; Kambayashi Y; Hidaka T; Tamabuchi E; Otake E; Tono H; Mizuashi M; Furudate S; Aiba S
J Dermatol; 2018 Feb; 45(2):e35-e36. PubMed ID: 28983948
[No Abstract] [Full Text] [Related]
45. Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature.
Mössner R; Zimmer L; Berking C; Hoeller C; Loquai C; Richtig E; Kähler KC; Hassel JC; Gutzmer R; Ugurel S
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1797-806. PubMed ID: 25752368
[TBL] [Abstract][Full Text] [Related]
46. Novel cutaneous effects of combination chemotherapy with BRAF and MEK inhibitors: a report of two cases.
Green JS; Norris DA; Wisell J
Br J Dermatol; 2013 Jul; 169(1):172-6. PubMed ID: 23413975
[TBL] [Abstract][Full Text] [Related]
47. Treatment of BRAF inhibitor-induced hyperkeratosis.
Battley JE; Lenihan E; Redmond HP; Murphy M; Power DG
Acta Oncol; 2013 May; 52(4):874-7. PubMed ID: 22998476
[No Abstract] [Full Text] [Related]
48. Two cases of immune thrombocytopenia associated with pembrolizumab.
Le Roy A; Kempf E; Ackermann F; Routier E; Robert C; Turpin A; Marabelle A; Mateus C; Michot JM; Lambotte O
Eur J Cancer; 2016 Feb; 54():172-174. PubMed ID: 26687374
[No Abstract] [Full Text] [Related]
49. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma.
Schadendorf D; Amonkar MM; Stroyakovskiy D; Levchenko E; Gogas H; de Braud F; Grob JJ; Bondarenko I; Garbe C; Lebbe C; Larkin J; Chiarion-Sileni V; Millward M; Arance A; Mandalà M; Flaherty KT; Nathan P; Ribas A; Robert C; Casey M; DeMarini DJ; Irani JG; Aktan G; Long GV
Eur J Cancer; 2015 May; 51(7):833-40. PubMed ID: 25794603
[TBL] [Abstract][Full Text] [Related]
50. A new standard of care for metastatic melanoma?
Sharma SP
Lancet Oncol; 2015 Jan; 16(1):e8. PubMed ID: 25638559
[No Abstract] [Full Text] [Related]
51. BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic Syndrome.
Perico L; Mandalà M; Schieppati A; Carrara C; Rizzo P; Conti S; Longaretti L; Benigni A; Remuzzi G
Am J Kidney Dis; 2017 Jul; 70(1):145-150. PubMed ID: 28242136
[TBL] [Abstract][Full Text] [Related]
52. BRAFV600E mutation status of involuting and stable nevi in dabrafenib therapy with or without trametinib.
McClenahan P; Lin LL; Tan JM; Flewell-Smith R; Schaider H; Jagirdar K; Atkinson V; Lambie D; Prow TW; Sturm RA; Soyer HP
JAMA Dermatol; 2014 Oct; 150(10):1079-82. PubMed ID: 24695877
[TBL] [Abstract][Full Text] [Related]
53. Is it good or bad to find a BRAF mutation?
Flaherty KT
J Clin Oncol; 2011 Apr; 29(10):1229-30. PubMed ID: 21343552
[No Abstract] [Full Text] [Related]
54. Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.
Parakh S; Murphy C; Lau D; Cebon JS; Andrews MC
J Clin Pharm Ther; 2015 Feb; 40(1):121-3. PubMed ID: 25382067
[TBL] [Abstract][Full Text] [Related]
55. BRAF V600 Mutational Status in Melanoma Correlates with Cytologic Features in Fine-Needle Aspirate Specimens.
Lee PJ; Dennis K; Madan R; Fan F
Acta Cytol; 2019; 63(1):10-16. PubMed ID: 30396186
[TBL] [Abstract][Full Text] [Related]
56. Paradoxical oncogenesis: are all BRAF inhibitors equal?
Menzies AM; Kefford RF; Long GV
Pigment Cell Melanoma Res; 2013 Sep; 26(5):611-5. PubMed ID: 23795808
[TBL] [Abstract][Full Text] [Related]
57. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway.
Huang V; Hepper D; Anadkat M; Cornelius L
Arch Dermatol; 2012 May; 148(5):628-33. PubMed ID: 22431713
[TBL] [Abstract][Full Text] [Related]
58. (18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma.
Carlino MS; Saunders CA; Haydu LE; Menzies AM; Martin Curtis C; Lebowitz PF; Kefford RF; Long GV
Eur J Cancer; 2013 Jan; 49(2):395-402. PubMed ID: 22981500
[TBL] [Abstract][Full Text] [Related]
59. Neutrophilic eccrine hidradenitis in two patients treated with BRAF inhibitors: a new cutaneous adverse event.
Herms F; Franck N; Kramkimel N; Fichel F; Delaval L; Laurent-Roussel S; Carlotti A; Avril MF
Br J Dermatol; 2017 Jun; 176(6):1645-1648. PubMed ID: 28005274
[TBL] [Abstract][Full Text] [Related]
60. Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors.
Vigarios E; Lamant L; Delord JP; Fricain JC; Chevreau C; Barrés B; Gomez-Roca C; Boulanger M; Sibaud V
Br J Dermatol; 2015 Jun; 172(6):1680-1682. PubMed ID: 25495246
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
